Podophyllotoxin: History, Recent Advances and Future Prospects.
Biomolecules
; 11(4)2021 04 19.
Article
in English
| MEDLINE | ID: covidwho-1206298
ABSTRACT
Podophyllotoxin, along with its various derivatives and congeners are widely recognized as broad-spectrum pharmacologically active compounds. Etoposide, for instance, is the frontline chemotherapeutic drug used against various cancers due to its superior anticancer activity. It has recently been redeveloped for the purpose of treating cytokine storm in COVID-19 patients. Podophyllotoxin and its naturally occurring congeners have low bioavailability and almost all these initially discovered compounds cause systemic toxicity and development of drug resistance. Moreover, the production of synthetic derivatives that could suffice for the clinical limitations of these naturally occurring compounds is not economically feasible. These challenges demanded continuous devotions towards improving the druggability of these drugs and continue to seek structure-optimization strategies. The discovery of renewable sources including microbial origin for podophyllotoxin is another possible approach. This review focuses on the exigency of innovation and research required in the global R&D and pharmaceutical industry for podophyllotoxin and related compounds based on recent scientific findings and market predictions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Podophyllotoxin
/
Anti-Infective Agents
/
Anti-Inflammatory Agents
/
Antineoplastic Agents, Phytogenic
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Biom11040603
Similar
MEDLINE
...
LILACS
LIS